Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary— Olomoucine (2‐(2‐hydroxyethylamino)‐6‐benzylamino‐9‐methylpurine) has been recently described as a competitive inhibitor (ATP‐binding site) of the cell cycle regulating p34 cdc2/cyclin B, p33 cdk2/cyclin A and p33 cdk2/cyclin E kinases, the brain p33 cdk5 p35 kinase and the ERK1AP‐kinase. The unusual specificity of this compound towards cell cycle regulating enzymes suggests that it could inhibit certain steps of the cell cycle. The cellular effects of olomoucine were investigated in a large variety of plant and animal models. This compound inhibits the G1S transition of unicellular algae (dinoflagellate and diatom). It blocks Fucus zygote cleavage and development of Laminaria gametophytes. Stimulated Petunia mesophyl protoplasts are arrested in G1 by olomoucine. By arresting cleavage it blocks the development of Calanus copepod larvae. It reversibly inhibits the early cleavages of Caenorhabditis elegans embryos and those of ascidian embryos. Olomoucine inhibits the serotonin‐induced prophase/metaphase transition of clam oocytes; furthermore, it triggers the release of these oocytes from their meiotic metaphase I arrest, and induces nuclei reformation. Olomoucine slows down the prophase/metaphase transition in cleaving sea urchin embryos, but does not affect the duration of the metaphase/anaphase and anaphase/telophase transitions. It also inhibits the prophase/metaphase transition of starfish oocytes triggered by various agonists. Xenopus oocyte maturation, the in vivo and in vitro phosphorylation of elongation factor EF‐1 are inhibited by olomoucine. Mouse oocyte maturation is delayed by this compound, whereas parthenogenetic release from metaphase II arrest is facilitated. Growth of a variety of human cell lines (rhabdomyosarcoma cell lines Rh1, Rh18, Rh28 and Rh30; MCF‐7, KB‐3‐1 and their adriamycin‐resistant counterparts; National Cancer Institute 60 human tumor cell lines comprising nine tumor types) is inhibited by olomoucine. Cell cycle parameter analysis of the non‐small cell lung cancer cell line MR65 shows that olomoucine affects G1 and S phase transits. Olomoucine inhibits DNA synthesis in interleukin‐2‐stimulated T lymphocytes (CTLL‐2 cells) and triggers a G1 arrest similar to interleukin‐2 deprivation. Both cdc2 and cdk2 kinases (immunoprecipitated from nocodazole‐ and hydroxyurea‐treated CTLL‐2 cells, respectively) are inhibited by olomoucine. Both yeast and Drosophila embryos were insensitive to olomoucine. Taken together the results of this Noah's Ark approach show that olomoucine arrests cells both at the G1S and the G2M boundaries, consistent with the hypothesis of a prevalent effect on the cdk2 and cdc2 kinases, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
The embryonic cell lineage of the nematode Caenorhabditis elegans
Sulston, J. E., Schierenberg, E., White, J. G., & Thomson, J. N. (1983) · Developmental Biology · doi:10.1016/0012-1606(83)90201-4 · Cited by 4,199
Self-citationA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
Cited by
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Self-citationDe Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Self-citationvan Engeland, M., Ramaekers, F. C. S., Schutte, B., & Reutelingsperger, C. P. M. (1996) · Cytometry · doi:10.1002/(sici)1097-0320(19960601)24:2<131::aid-cyto5>3.0.co;2-m · Cited by 535
Self-citationCalegari, F., & Huttner, W. B. (2003) · Journal of Cell Science · doi:10.1242/jcs.00825 · Cited by 366
Metadata
- Authors
- Abraham, R., Acquarone, M., Andersen, A., Asensi, A., Bellé, R., Berger, F., Bergounioux, C., Brunn, G., Buquet‐Fagot, C., Fagot, D., Glab, N., Goudeau, H., Goudeau, M., Guerrier, P., Houghton, P., Hendriks, H., Kloareg, B., Lippai, M., Marie, D., Maro, B., Meijer, L., Mester, J., Mulner‐Lorillon, O., Poulet, S., Schierenberg, E., Schutte, B., Vaulot, D., & Verlhac, M.
- Venue
- Biology of the Cell
- Publisher
- Wiley
- Published
- 1995-01
- Volume
- 83
- Issue
- 2-3
- Pages
- 105-120
- ISSN
- 0248-4900 (ISSN-L)
- 1768-322X
- OpenAlex
- W1983202900
- Cited by
- 140
- References
- 6
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases. https://app.cochat.ai/papers/10.1016/0248-4900(96)81298-6
- The paper
- Abraham, R., Acquarone, M., Andersen, A., Asensi, A., Bellé, R., Berger, F., Bergounioux, C., Brunn, G., Buquet‐Fagot, C., Fagot, D., Glab, N., Goudeau, H., Goudeau, M., Guerrier, P., Houghton, P., Hendriks, H., Kloareg, B., Lippai, M., Marie, D., . . . Verlhac, M. (1995). Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases. Biology of the Cell. https://doi.org/10.1016/0248-4900(96)81298-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.